MedTrace Logo

A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354

NCT00638989 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-05-04

Study results available
· View outcomes & findings →

Summary

To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.

Conditions

Interventions

BIOLOGICAL

CAT-354 150 mg (intravenous)

A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.

BIOLOGICAL

CAT-354 150 mg (subcutaneous)

A single dose of CAT-354 150 mg injection subcutaneously on Day 0.

BIOLOGICAL

CAT-354 300 mg (subcutaneous)

A single dose of CAT-354 300 mg injection subcutaneously on Day 0.

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • MedImmune LLC · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-11
Primary Completion
2008-06-07
Completion
2008-06-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638989 on ClinicalTrials.gov